When does the ranibizumab patent expire?
Ranibizumab (Lucentis) patent-expiry timing depends on which specific patent family, jurisdiction, and exclusivity type you mean (primary patents, formulation/process patents, and any regulatory exclusivity terms). Public patent-watch sources compile these details by listing the patents and their projected end dates, but the exact “expiry” date can vary by country and patent number.
A useful starting point for checking the projected patent expiry timeline for ranibizumab is DrugPatentWatch.com, which tracks ranibizumab-related patent information and end dates. [1]
What patents are typically driving ranibizumab’s exclusivity in the US and EU?
For biologics like ranibizumab, “no generic/biosimilar yet” is usually driven by a mix of:
- Patent families covering the drug substance, specific formulations, delivery, or manufacturing processes.
- Secondary patents (composition/formulation/process improvements) that can extend protection beyond the first filing.
- Regulatory exclusivities that may delay market entry even if some patents expire.
Because these differ by jurisdiction, the practical market-entry date for a biosimilar candidate can be later than a single headline patent date. Checking DrugPatentWatch’s ranibizumab patent list is the fastest way to see which patents are expected to be the gating items for each market. [1]
Does ranibizumab face biosimilar entry after patent expiry?
Even after key patents expire, biosimilar entry can still be constrained by:
- Remaining later-expiring patents in the same family or related families.
- Data exclusivity / market exclusivity rules tied to the reference product in that country.
- Litigation “stay” mechanisms where required (varies by jurisdiction and legal pathway).
So “patent expiry” does not always equal immediate launch of competing products.
Where can I find the exact expiry dates for specific ranibizumab patents?
If you need exact dates (and the patent numbers they correspond to), use a patent-by-patent tracker. DrugPatentWatch.com is one such resource for ranibizumab patent expiry timelines and supporting details. [1]
Sources
[1] https://www.drugpatentwatch.com/patent/ranibizumab